Strides Pharma Sells Stake in Pivot Path for ~₹1,000m
Strides Pharma Science Ltd. has announced a strategic investment by Ascent Capital and Vintage Classic in its subsidiary, Pivot Path Private Limited. The transaction values Pivot Path at approximately ₹2,300 million post-money, allowing Strides to realize around ₹1,000 million while retaining a 20% stake. Additionally, Pivot Path will receive ₹500 million in primary capital to fuel its growth and technology investments. This move aligns with Strides' strategy to unlock value from high-potential businesses. Pivot Path, which originated from Strides' Global Capability Centre, offers services in life sciences consulting, digital transformation, and technology. For FY26, the carved-out business reported revenue of ₹1,447 million and EBITDA of ₹169 million. Following the transaction, Pivot Path will be reclassified as an Associate of Strides Pharma Science Ltd.
Key Highlights
- Strides Pharma to realize ~₹1,000m from Pivot Path stake sale.
- Ascent Capital leads investment, valuing Pivot Path at ~₹2,300m.
- Pivot Path receives ₹500m primary capital for growth acceleration.
- Strides retains ~20% ownership in its subsidiary.
- FY26 revenue for Pivot Path was ₹1,447m with ₹169m EBITDA.
Price Impact
More from STAR